Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population

Table 1

Baseline data of patient characteristics in three groups.

	End-stage PDR		Normals (𝑛=151)
	Yes (𝑛=153)	No (𝑛=123)
Male (n[%])	62 (40.523)^⋇	48 (39.024)^⋇	63 (41.722)
Age, years^#	52.719 ± 6.661^⋇§	57.626 ± 8.006*	53.136 ± 7.342
PAI-1, pmol/dL^#	7.394 ± 2.084^*§	6.216 ± 0.989*	1.952 ± 0.276
95%CI	7.062–7.727	6.040–6.393	1.851–2.053
Family history of DM (n[%])	13 (8.497)^§	36 (29.268)	—
History of hypertension (n[%])	89 (58.170)^§	75 (60.976)	—
Smoking (n[%])
Active	61 (39.869)	46 (37.398)	—
Passive	153 (100.000)	123 (100.000)	—
Duration of DM^#	12.496 ± 6.173^§	9.954 ± 4.441	—
FBG, mmol/L^#	7.125 ± 1.987^§	6.512 ± 2.157	—
PBG, mmol/L^#	9.919 ± 3.401	9.226 ± 3.786	—
SBP, mmHg^#	136.272 ± 11.114^§	131.952 ± 14.719	—
DBP, mmHg^#	84.771 ± 6.985^§	82.602 ± 9.373	—
TC, mmol/L^#	5.161 ± 0.784	5.222 ± 1.101	—
TG, mmol/L^#	2.115 ± 1.509	1.854 ± 1.628	—
CREA, umol/L^#	82.971 ± 52.230^§	70.085 ± 33.491	—
BUN, mmol/L^#	6.890 ± 2.630	6.345 ± 2.242	—
PAI-1, pmol/dL^#	7.394 ± 2.084^§	6.216 ± 0.989	—
WBC, 10^9/L^#	6.709 ± 1.606	6.513 ± 1.953	—
RBC, 10^12/L^#	4.350 ± 0.396	4.347 ± 0.563	—
HGB, g/L^#	54.831 ± 65.599	130.452 ± 18.130	—
Lymphocyte counts, 10^9/L^#	7.643 ± 2.164^§	1.784 ± 0.555	—
MPV, ^#	9.871 ± 0.792^§	10.192 ± 0.971	—

^*𝑃<0.01 versus normals; ^§𝑃<0.05 versus no end-stage PDR; ^⋇𝑃>0.05 versus normal.
^#Continuous variables are presented as the mean with the standard deviation.